InMed Pharmaceuticals Files Patent Application for Treatment of Neurodegenerative Diseases with Rare Cannabinoid

  • InMed Pharmaceuticals has filed an international patent application that specifies a rare cannabinoid that may inhibit or slow the progression of neurodegenerative disease and potentially enhance the neuronal function
  • With neurogenerative diseases affecting millions worldwide and the cost of treating expected to rise in the future, finding treatments and cures is a matter of increasing urgency
  • InMed’s patent application is a promising start, expanding the company’s patent portfolio, which currently includes twelve patent families

InMed Pharmaceuticals (NASDAQ: INM), a global leader in the manufacturing and pharmaceutical development of rare cannabinoids, recently filed a Patent Cooperation Treaty (“PCT”) application, titled “Compositions and Methods for Treating Neuronal Disorders with ” (https://cnw.fm/4mWW0).

More InMed Pharmaceuticals Files Patent Application for Treatment of Neurodegenerative Diseases with Rare Cannabinoid